嵌合抗原受体
机制(生物学)
细胞
计算机科学
癌症
免疫疗法
医学
计算生物学
生物信息学
生物
遗传学
认识论
内科学
哲学
作者
Oren Barboy,Yonatan Katzenelenbogen,Rotem Shalita,Ido Amit
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-05-23
卷期号:13 (7): 1546-1555
被引量:4
标识
DOI:10.1158/2159-8290.cd-23-0010
摘要
Chimeric antigen receptor (CAR) T therapies hold immense promise to revolutionize cancer treatment. Nevertheless, key challenges, primarily in solid tumor settings, continue to hinder the application of this technology. Understanding CAR T-cell mechanism of action, in vivo activity, and clinical implications is essential for harnessing its full therapeutic potential. Single-cell genomics and cell engineering tools are becoming increasingly effective for the comprehensive research of complex biological systems. The convergence of these two technologies can accelerate CAR T-cell development. Here, we examine the potential of applying single-cell multiomics for the development of next-generation CAR T-cell therapies.Although CAR T-cell therapies have demonstrated remarkable clinical results in treating cancer, their effectiveness in most patients and tumor types remains limited. Single-cell technologies, which are transforming our understanding of molecular biology, provide new opportunities to overcome the challenges of CAR T-cell therapies. Given the potential of CAR T-cell therapy to tip the balance in the fight against cancer, it is important to understand how single-cell multiomic approaches can be leveraged to develop the next generations of more effective and less toxic CAR T-cell products and to provide powerful decision-making tools for clinicians to optimize treatment and improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI